PGAP2: A Protein Involved in GPCR Signaling and Neurotransmission

Target Name: PGAP2

NCBI ID: G27315

PGAP2

PGAP2: A Protein Involved in GPCR Signaling and Neurotransmission

PGAP2 (short for Post-Graduate Group-Amino Acid Pyrimidine Carboxylic Acid Sulfhydrate), is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. It is a member of the G-protein -coupled receptor (GPCR) family, which is a large superfamily of transmembrane and intracellular receptors that play a crucial role in cellular signaling.

PGAP2 is a 21-kDa protein that is characterized by its ability to activate GPCR signaling pathways. This is achieved through its extracellular domain, which consists of a long N-terminal region that contains a leucine-rich repeat (LRR) and a calmodulin- binding protein (CBP) domain. The LRR is a common structural motif that is found in several GPCR family proteins, while the CBP domain is a unique structural feature that is specific to PGAP2.

PGAP2 is involved in a wide range of physiological processes in the body, including cell signaling, neurotransmission, and stress response. It is a negative regulator of the neurotransmitter dopamine, which is involved in the regulation of motivation, pleasure, and reward. PGAP2 has has been shown to play a role in the regulation of dopamine release from terminals in the brain, and it has been implicated in the development of various neurological disorders, including Parkinson's disease and addiction.

In addition to its role in neurotransmission, PGAP2 is also involved in the regulation of inflammation and cellular signaling pathways. It has been shown to play a role in the regulation of inflammation in the liver, and it has been implicated in the development of various inflammatory diseases, including autoimmune diseases and cancer.

PGAP2 is also a potential drug target in several diseases. Its ability to activate GPCR signaling pathways makes it a promising target for the development of therapeutic agents that can treat a wide range of conditions. For example, PGAP2 has been shown to be involved in the Regulation of dopamine release from terminals in the brain, which makes it a potential target for the treatment of Parkinson's disease. Additionally, its role in the regulation of inflammation makes it a potential target for the treatment of various inflammatory diseases.

PGAP2 is also a potential biomarker for several diseases. Its expression is often reduced in the brains of individuals with certain neurological disorders, such as Parkinson's disease and Alzheimer's disease. This suggests that PGAP2 may be a useful biomarker for the diagnosis and assessment of these conditions . Additionally, its involvement in the regulation of dopamine release from terminals in the brain makes it a potential biomarker for the treatment of addiction and other behavioral disorders.

In conclusion, PGAP2 is a well-characterized protein that is involved in a wide range of physiological processes in the body. Its ability to activate GPCR signaling pathways makes it a promising target for the development of therapeutic agents that can treat a wide range of conditions . Additionally, its role in the regulation of inflammation makes it a potential target for the treatment of various inflammatory diseases. As a potential drug target and biomarker, PGAP2 is a promising target for the development of new therapies for a wide range of conditions.

Protein Name: Post-GPI Attachment To Proteins 2

Functions: Involved in the lipid remodeling steps of GPI-anchor maturation. Required for stable expression of GPI-anchored proteins at the cell surface

The "PGAP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PGAP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets